LLMs-Healthcare : Current Applications and Challenges of Large Language Models...

Title: LLMs in healthcare: a broad survey that skips the deployment hard parts

Introduction

I read arXiv:2311.12882 because surveys matter. Clinicians, product teams, and regulators are all asking the same question: where do large language models actually help in medicine, and where do they create new risks? This paper tries to answer that by cataloging applications of LLMs across specialties such as cancer care, dermatology, dental care, neurodegenerative disorders, and mental health, and by listing challenges and data types. It is a useful map for someone new to the topic, but it does not get into the places where projects succeed or fail in real clinical settings.

Technical summary of the paper

The authors present a narrative review of how LLMs are being applied in healthcare. They organize applications by specialty and by function, with particular attention to diagnostic and treatment-related roles. The paper highlights examples where models can support literature synthesis, clinical note generation, patient education, triage, and specialty-specific tasks. It calls out common challenges such as hallucination, data privacy, bias, and the need to handle diverse data modalities. There is also an overview of input data types used in medical contexts, from unstructured notes and imaging captions to structured EHR fields.

The paper does not present new benchmarks or original experiments. Its contribution is the synthesis and classification of reported uses and obstacles. That is a legitimate contribution, provided the reader understands the limits of a narrative survey.

My analysis and perspective

What I appreciate about this review is its breadth. Having a single document that lists reported uses in oncology, dermatology, neurology, dentistry, and psychiatry helps people see recurring themes. It correctly flags the three big, recurring failure modes I see working with clinical teams: factual errors framed as confident conclusions, training data blind spots that produce biased outputs, and the gap between a research prototype and a deployable, audited system.

However, breadth exposes the paper’s shallow spots. There is little assessment of evidence quality. For the clinical reader what matters most is not whether an LLM can produce a plausible-sounding treatment recommendation in a toy setting, but whether its use changes patient outcomes in prospective, controlled testing. The review lists applications and individual studies but does not weigh study design, sample size, external validation, or clinical endpoints. That makes it hard to use this paper to inform a deployment decision.

The paper notes hallucination and bias as problems. But it stops short of practical mitigation strategies that matter in production. For example, it does not discuss retrieval-augmented architectures as a way to ground outputs in evidence, or the operational controls needed to avoid silent failures: logging, provenance of model outputs, fallbacks to human review, and real-time monitoring for distribution shift. These are not academic niceties. They are the features that determine whether a system can run in a hospital without creating legal and safety troubles.

There are specialty-specific issues the review raises but does not interrogate deeply. In dermatology, skin tone representation in training data is a known cause of poor generalization. The paper mentions bias but does not emphasize the clinical severity of misdiagnosis across skin tones. In mental health, the review lists possible uses in screening and psychoeducation. It does not stress how a model that offers incorrect reassurance or misses suicidal ideation can cause harm. The difference between a model that assists a clinician and one that replaces judgment is where these papers should focus.

I also found the treatment of multimodal data cursory. Clinical problems rarely reduce to plain text prompts. Images, labs, time series, and device data matter. The review mentions handling diverse data types but does not provide a framework for multimodal alignment, temporal consistency, or the engineering trade-offs involved when you combine a language model with imaging models and structured EHR data.

Finally, regulatory and practical deployment concerns get too little attention. For health systems asking whether to pilot an LLM, cost, latency, auditability, data residency, and incident response plans are the first questions. The paper names regulatory risk, but it does not translate that into design principles: minimal scope, human-in-the-loop, explicit logging, and performance thresholds tied to clinical endpoints.

What matters for practice

If you are a clinician or engineering leader using this review to make decisions, here is what I would take from it. Use the paper as a map of reported research activity. Do not use it as an evidence base for deployment. Focus effort on narrow, well-scoped tasks where the output is easily checked by a clinician, such as drafting discharge summaries or surfacing relevant literature. Build systems so that every model assertion can be traced to source documents and so that clinicians can override outputs without friction.

For researchers, stop publishing bench-level demonstrations alone. Funded pilots should report prospective measures and safety monitoring. For vendors and startups, be transparent about training data, provide factuality measures, and adopt audit logging as a default.

The review is a useful starting point for people new to LLMs in medicine. It catalogues activity and raises the obvious risks. The missing piece is the operational detail. In clinical AI that is where projects either deliver value or create harm. I would like to see a follow-up that grades evidence quality, describes engineering controls used in successful pilots, and gives concrete evaluation metrics beyond plausibility and accuracy.

In short, arXiv:2311.12882 is a competent high-level survey. It helps you understand where people are pointing LLMs in medicine. If you are planning to build, deploy, or regulate one of these systems, you should read it and then go look for the next layer down: prospective trials, failure mode analyses, and deployment playbooks. Those are the things that determine whether LLMs help patients or create downstream risk.